NexImmune holds an exclusive license to foundational inventions for composition and use of aAPC developed by Johns Hopkins University. In addition, the Company owns a broad set of filed patents covering all aspect of the AIM™ technology and our products. The portfolio consists of multiple issued US patents, several issued patents in other countries, and dozens of pending patents in the US and elsewhere.


Peer Reviewed Publications

Perica, K., Bieler, J.G., Schütz, C., Varela, J.C., Douglass, J., Skora,A., Chiu, Y.L., Oelke, M., Kinzler, K., Zhou, S., Vogelstein, B., Schneck, J.P. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano (2015) 10.1021/5b02829

Perica, K., Tu, A., Richter, A., Bieler, J.G, Edidin, M., Schneck, J.S. Magnetic-field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity in vivo. ACS Nano (2014) 10.1021/nn405520d

Sunshine, JC, Perica, K, Schneck, JP, Green, JJ. Particle shape dependence of CD8þ T cell activation by artificial antigen presenting cells. Biomaterials, 35 (2014) 269e277.

Perica, K, De León Mederob, A, Duraib, M, Chiub, YL, Glick Bielerb, J, Sibenerb, L, Niemöllerc, M, Assenmacherc, M, Richterc, A, Edidind, M, Oelkeb, M, Schneck, J. Nanoscale artificial antigen presenting Cells for T cell immunotherapy. Nanomedicine, 10(1)(2014):119-129.

Shena, C, Chenga, K, Miaoa, S, Wanga, W, Heb, Y, Mengb, F, Zhangb, J. Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth. Immunology Letters, 150 (2013) 1–11.

Chiu Y, Schneck JP, Oelke M. HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL Journal Visual Experiments, 50 (2011).

Jessica B. Lee, Mathias Oelke, Lakshmi Ramachandra, David H. Canaday, Jonathan P. Schneck. Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immuno Ageing, 2011 Aug 16;8:6

Ndhlovu ZM, Oelke M, Schneck JP, Griffin DE. Dynamic regulation of functionally distinct virus-specific T cells. Proceedings of the National Academy of Science, 107(8):3669-74, 2010.

Yue C, Oelke M, Schneck J, Paulaitis ME. Novel cellular microarray assay for profiling T-cell peptide antigen specificities. Journal of Proteome Research, 9(11):5629-37, 2010.

Giuntoli II RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Research, 29(8):2875-84, 2009.

Tonya J. Webb, Joan G. Bieler, Jonathan P. Schneck, and Mathias Oelke. Ex vivo induction and expansion of Natural Killer T cells by CD1d1-Ig coated artificial antigen presenting cells. Journal of Immunological Methods, 31;346(1-2):38-44, 2009.

Ndhlovu ZM, Angenendt M, Heckel D, Schneck JP, Griffin DE, Oelke M. Development of an artificial antigen-presenting cell (aAPC)-based assay for the detection of low frequency virus-specific CD8+ T cells in whole blood with application to measles virus Clinical Vaccine Immunology, 16(7):1066-73, 2009.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V. In vivo administration of artificial Antigen Presenting Cells activates low-avidity T cells for treatment of cancer. Cancer Research, 15(69): 9376-84, 2009.

Schutz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. Killer-artificial-antigen presenting-cells (KaAPC): A novel strategy to delete specific T cells. Blood, 111(7):3546-52, 2008.

Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunology and Immunotherapy, 58(2):209-20,2008.

Webb TJ, Giuntoli II RL, Rogers O, Schneck JP, Oelke M. Ascites specific inhibition of CD1d-mediated activation of NKT cells. Clinical Cancer Research, 14(23):7652-8, 2008.

Paine A, Oelke M, Blasczyk R, Eiz-Vesper B. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells using artificial antigen presenting cells. Transfusion, 47:2143-215, 2007.

Karabekin Z, Lytton SD, Silver PB, Sergeev YV, Schneck JP, Caspi RR. Antigen/MHC Class II/Ig dimers for study of uveitogenic T Cells IRBP p161-180 presented by both IA & IE molecules. Investigative Opthamology & Visual Science, Vol. 46 (10): 3769-3776, 2005.

Oelke M and Schneck JP. HLA-Ig based artificial antigen-presenting cells: Setting the terms of engagement. Journal of Clinical Immunology, 110(3):243-51, 2004.

Oelke M, Maus MV, Didiano D, June C, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig coated artificial Antigen Presenting Cells. Nature Medicine, 9(5):619-24, 2003.

Multiple Studies Support Therapeutic and Diagnostic Utility


Review Articles

Schütz C, Oelke M, Schneck JP, Mackensen A, Fleck M. Killer-artificial-Antigen Presenting-Cells (KaAPC): The synthetic embodiment of a “guided missile” Future Medicine – Immunotherapy, 2(4):539-50, 2010.

Oelke M, Schneck JP. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion. Immunol Res. 2010 Jul; 47(1-3):248-56.

Mathias Oelke, Christine Krueger and Jonathan P. Schneck Technological Advances in Adoptive Immunotherapy, Drugs of Today, 41:13-21, Jan. 2005.

Mathias Oelke, Christine Krueger, Robert L.Giuntoli II and Jonathan P. Schneck Artificial antigen-presenting cells (aAPCs): artificial solutions for real diseases. Trends in Molecular Medicine 2005 Sep;11(9):412-20.

Mathias Oelke, and Jonathan P. Schneck. Immunotherapy With Enhanced Self Immune Cells, Discovery Medicine, 4 (22): 203-7, June-August 2004.

Krueger C, Schneck JP, Oelke M. Quality and quantity: New strategies to improve immunotherapy of cancer. Trends in Molecular Medicine, 10(5):205-8, 2004.